The human HER-2 gene encodes a putative transmembrane growth factor receptor (p185 protein) that is closely related to the epidermal growth factor receptor protein. Both HER-2 oncogene amplification and oncoprotein overexpression have been correlated with breast, ovarian, gastric, lung, and other cancers. In 15-40 % of primary breast cancers, amplification of the HER-2 oncogen is found which is highly correlated with overexpression of the encoded protein and seems to play a major role especially during the initiation of ductal carcinomas. HER-2 overexpression is described as independent prognostic factor with greater predictive power than most of the currently used prognostic tools - especially in axillary lymph-node-positive breast cancer patients. 32 % of ovarian carcinomas overexpress the HER-2 oncoprotein. Survival of those patients is significantly worse compared with cases of normal HER-2 protein expression. Additionally, patients whose tumors have high HER-2 protein expression are significantly less likely to have a complete response to primary therapy. A correlation between HER-2 expression, and clinical outcome has been also demonstrated for head and neck, salivary gland and placental carcinomas. HER-2 is useful in identifying cancer cells with increased aggressiveness. Soluble p97-115 HER-2 (the soluble circulating fragment of p185 HER-2) protein levels in serum can be used as diagnostic tool for monitoring the extent of tumor spread, postoperative relapse and/or metastatic risk for different cancers. Sample Types: Human amniotic fluids, cell culture, EDTA plasma, heparin plasma, serum. Sample Size: 100 μL. Range: 0.16-10 ng/mL. Sensitivity: 0.06 ng/mL. Time: 2hr 10min
Size
96 wells
Concentration
n/a
Applications
Immunoassays. Research Use Only. Not for Use in Diagnostic Procedures.